Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes

Journal of Medicinal Chemistry

Volumn 55, Issue 8, 2012, Pages 3756-3776

  Mikami, Satoshi ^a   Kitamura, Shuji ^a   Negoro, Nobuyuki ^a   Sasaki, Shinobu ^a   Suzuki, Masami ^a   Tsujihata, Yoshiyuki ^a   Miyazaki, Takeshi ^a   Ito, Ryo ^a   Suzuki, Nobuhiro ^a   Miyazaki, Junichi ^a   Santou, Takashi ^a   Kanzaki, Naoyuki ^a   Funami, Miyuki ^a   Tanaka, Toshimasa ^a   Yasuma, Tsuneo ^a   Momose, Yu ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 FLUORO 4 [[[4' [(4 HYDROXY 1,1 DIOXIDOTETRAHYDRO 2H THIOPYRAN 4 YL)METHOXY] 2',6' DIMETHYLBIPHENYL 3 YL]METHYL]AMINO]PHENYL]PROPANOIC ACID; BIPHENYL DERIVATIVE; FATTY ACID; G PROTEIN COUPLED RECEPTOR 40; GLIBENCLAMIDE; ORAL ANTIDIABETIC AGENT; PROPIONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG POTENCY; FEASIBILITY STUDY; FEMALE; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; IMPAIRED GLUCOSE TOLERANCE; INSULIN LIKE ACTIVITY; LIPOPHILICITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; RAT;

ANIMALS; CALCIUM; CASPASES; CELL SURVIVAL; CHO CELLS; CRICETINAE; CYCLIC S-OXIDES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE INTOLERANCE; HEP G2 CELLS; HUMANS; HYPOGLYCEMIC AGENTS; INHIBITORY CONCENTRATION 50; MALE; PHENYLPROPIONATES; RATS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84860270451     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm2016123     Document Type: Article

References (60)

1. Taylor, S. I.; Accili, D.; Imai, Y. Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 1994, 43, 735-740
2. Groop, L. C.; Widen, E.; Ferrannini, E. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods? Diabetologia 1993, 36, 1326-1331 (Pubitemid 23353035)
3. Groop, L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion Int. J. Clin. Pract., Suppl. 2000, 113, 3-13
4. Gerich, J. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity Endocr. Rev. 1998, 19, 491-503 (Pubitemid 29116017)
5. Ikenoue, T.; Okazaki, K.; Fujitani, S.; Tsuchiya, Y.; Akiyoshi, M.; Maki, T.; Kondo, N. Effect of a new hypoglycemic agent, A-4166 [(-)- N -(trans -4-isopropylcyclohexanecarbonyl)- d -phenylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenblamide Biol. Pharm. Bull. 1997, 20, 354-359 (Pubitemid 27212992)
6. Rendell, M. The role of sulphonylureas in the management of type 2 diabetes mellitus Drugs 2004, 64, 1339-1358 (Pubitemid 38916346)
7. Asplund, K.; Wiholm, B. E.; Lithner, F. Glibenclamide-associated hypoglycaemia: a report on 57 cases Diabetologia 1983, 24, 412-417
8. Ferner, R. E.; Neil, H. A. Sulphonylureas and hypoglycaemia Br. Med. J. (Clin. Res. Ed.) 1988, 296, 949-950 (Pubitemid 18093424)
9. Maedler, K.; Carr, R. D.; Bosco, D.; Zuellig, R. A.; Berney, T.; Donath, M. Y. Sulfonylurea induced beta-cell apoptosis in cultured human islets J. Clin. Endocrinol. Metab. 2005, 90, 501-506 (Pubitemid 40116700)
10. Del Guerra, S.; Marselli, L.; Lupi, R.; Boggi, U.; Mosca, F.; Benzi, L.; Del Prato, S.; Marchetti, P. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets J. Diabetes Complications 2005, 19, 60-64 (Pubitemid 40092372)
11. Drucker, D. J.; Nauck, M. A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006, 368, 1696-1705 (Pubitemid 46048557)
12. Warnotte, C.; Gilon, P.; Nenquin, M.; Henquin, J. C. Mechanisms of the stimulation of insulin release by saturated fatty acids: a study of palmitate effects in mouse β-cells Diabetes 1994, 43, 703-711 (Pubitemid 24138785)
13. Prentki, M; Joly, E.; El-Assaad, W.; Roduit, R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes Diabetes 2002, 51 (Suppl 3) S405-S413
14. Roduit, R.; Nolan, C.; Alarcon, C.; Moore, P.; Barbeau, A.; Delghingaro-Augusto, V.; Przybykowski, E.; Morin, J.; Massé, F.; Massie, B.; Ruderman, N.; Rhodes, C.; Poitout, V.; Prentki, M. A role for the malonyl-CoA/long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and nonfuel stimuli Diabetes 2004, 53, 1007-1019 (Pubitemid 38436613)
15. Turk, J.; Gross, R. W.; Ramanadham, S. Amplification of insulin secretion by lipid messengers Diabetes 1993, 42, 367-374 (Pubitemid 23066511)
16. Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; Tanaka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Komatsu, H.; Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; Fujisawa, Y.; Fujino, M. Free fatty acids regulate insulin secretion from pancreatic β cells through GPR40 Nature 2003, 422, 173-176 (Pubitemid 36362750)
17. Briscoe, C. P.; Tadayyon, M.; Andrews, J. L.; Benson, W. G.; Chambers, J. K.; Eilert, M. M.; Eillis, C.; Elshourbagy, N. A.; Goetz, A. S.; Minnick, D. T.; Murdock, P. R.; Sauls, H. R., Jr.; Shabon, U.; Spinage, L. D.; Strum, J. C.; Szekeres, P. G.; Tan, K. B.; Way, J. M.; Ignar, D. M.; Wilson, S.; Muir, A. I. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids J. Biol. Chem. 2003, 278, 11303-11311 (Pubitemid 36792687)
18. Kotarsky, K.; Nilsson, N. E.; Flodgren, E.; Owman, C.; Olde, B. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs Biochem. Biophys. Res. Commun. 2003, 301, 406-410 (Pubitemid 36279253)
19. Stoddart, L. A.; Smith, N. J.; Milligan, G. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions Pharmacol. Rev. 2008, 60, 405-417
20. Prentki, M.; Tornheim, K.; Corkey, B. E. Signal transduction mechanisms in nutrient-induced insulin secretion Diabetologia 1997, 40, S32-S41
21. Zawalich, W. S.; Zawalich, K. C. Regulation of insulin secretion by phospholipase C Am. J. Physiol. Endocrinol. Metab. 1996, 271, E409-E416
22. 2+ channel and link to insulin release Am. J. Physiol. Endocrinol. Metab. 2005, 289, E670-E677
23. Shapiro, H.; Shachar, S.; Sekler, I.; Hershfinkel, M.; Walker, M. D. Role of GPR40 in fatty acid action on the β cell line INS-1E Biochem. Biophys. Res. Commun. 2005, 335, 97-104 (Pubitemid 41350767)
24. Schnell, S.; Schaefer, M.; Schofl, C. Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from beta-cells through activation of GPR40 Mol. Cell. Endocrinol. 2007, 263, 173-180 (Pubitemid 44834553)
25. Nagasumi, K.; Esaki, R.; Iwachidow, K.; Yasuhara, Y.; Ogi, K.; Tanaka, H.; Nakata, M.; Yano, T.; Shimakawa, K.; Taketomi, S.; Takeuchi, K.; Odaka, H.; Kaisho, Y. Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice Diabetes 2009, 58, 1067-1076
26. Briscoe, C. P.; Peat, A. J.; McKeown, S. C.; Corbett, D. F.; Goetz, A. S.; Littleton, T. R.; McCoy, D. C.; Kenakin, T. P.; Andrews, J. L.; Ammala, C.; Fornwald, J. A.; Ignar, D. M.; Jenkinson, S. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules Br. J. Pharmacol. 2006, 148, 619-628 (Pubitemid 43993052)
27. Tan, C. P.; Feng, Y.; Zhou, Y. P.; Eiermann, G. J.; Petrov, A.; Zhou, C.; Lin, S.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T. E.; Einstein, M.; Kumar, S.; Berger, J. P.; Mills, S. G.; Thornberry, N. A.; Yang, L.; Howard, A. D. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice Diabetes 2008, 57, 2211-2219
28. Tsujihata, Y.; Ito, R.; Suzuki, M.; Harada, A.; Negoro, N.; Yasuma, T.; Momose, Y.; Takeuchi, K. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats J. Pharmacol. Exp. Ther. 2011, 339, 228-237
29. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist ACS Med. Chem. Lett. 2010, 1, 290-294
30. Sasaki, S.; Kitamura, S.; Negoro, N.; Suzuki, M.; Tsujihata, Y.; Suzuki, N.; Santou, T.; Kanzaki, N.; Harada, M.; Tanaka, Y.; Kobayashi, M.; Tada, N.; Funami, M.; Tanaka, T.; Yamamoto, Y.; Fukatsu, K.; Yasuma, T.; Momose, Y. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists J. Med. Chem. 2011, 54, 1365-1378
31. Miret, M.; de Groene, E. M.; Klaffke, W. Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2 J. Biomol. Screening 2006, 11, 184-193
32. Bugelski, P. J.; Atif, U.; Molton, S.; Toeg, I.; Lord, P. G.; Morgan, D. G. A strategy for primary high throughput cytotoxicity screening in pharmaceutical toxicology Pharm. Res. 2000, 17, 1265-1272
33. Ekwall, B. Overview of the final MEIC results: II. The in vitro-in vivo evaluation, including the selection of a practical battery of cell tests for prediction of acute lethal blood concentrations in humans Toxicol. in Vitro 1999, 13, 665-673 (Pubitemid 29354194)
34. Walum, E.; Hedander, J.; Garberg, P. Research perspectives for pre-screening alternatives to animal experimentation: on the relevance of cytotoxicity measurements, barrier passage determinations and high throughput screening in vitro to select potentially hazardous compounds in large sets of chemicals Toxicol. Appl. Pharmacol. 2005, 207, S393-S397
35. Bharate, S. B.; Nemmani, K. V.; Vishwakarma, R. A. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes Expert Opin. Ther. Pat. 2009, 19, 237-264
36. Garrido, D. M.; Corbett, D. F.; Dwornik, K. A.; Goetz, A. S.; Littleton, T. R.; McKeown, S. C.; Mills, W. Y.; Smalley, T. L., Jr.; Briscoe, C. P.; Peat, A. J. Synthesis and activity of small molecule GPR40 agonists Bioorg. Med. Chem. Lett. 2006, 16, 1840-1845 (Pubitemid 43267362)
37. Zhou, C.; Tang, C.; Chang, E.; Ge, M.; Lin, S.; Cline, E.; Tan, C. P.; Feng, Y.; Zhou, Y. P.; Eiermann, G. J.; Petrov, A.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T. E.; Einstein, M.; Kumar, S.; Berger, J.; Howard, A. D.; Thornberry, N.; Mills, S. G.; Yang, L. Discovery of 5-aryloxy-2,4- thiazolidinediones as potent GPR40 agonists Bioorg. Med. Chem. Lett. 2010, 20, 1298-1301
38. Song, F.; Lu, S.; Gunnet, J.; Xu, J. Z.; Wines, P.; Proost, J.; Liang, Y.; Baumann, C.; Lenhard, J.; Murray, W. V.; Demarest, K. T.; Kuo, G. H. Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists J. Med. Chem. 2007, 50, 2807-2817 (Pubitemid 46980852)
39. Morrison, H.; Jona, J.; Walker, S. D.; Woo, J. C. S.; Li, L.; Fang, J. Development of a suitable salt form for a GPR40 receptor agonist Org. Process Res. Dev. 2011, 15, 104-111
40. Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Merten, N.; Pfleiderer, M.; Karlsen, K. K.; Rasmussen, S. S.; Steensgaard, M.; Hamacher, A.; Schmidt, J.; Drewke, C.; Petersen, R. K.; Kristiansen, K.; Ullrich, S.; Kostenis, E.; Kassack, M. U.; Ulven, T. Structure-activity study of dihydrocinnamic acids and discovery of the potent FFA1 (GPR40) agonist TUG-469 ACS Med. Chem. Lett. 2010, 1, 345-349
41. Christiansen, E.; Urban, C.; Merten, N.; Liebscher, K.; Karlsen, K. K.; Hamacher, A.; Spinrath, A.; Bond, A. D.; Drewke, C.; Ullrich, S.; Kassack, M. U.; Kostenis, E.; Ulven, T. Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes J. Med. Chem. 2008, 51, 7061-7064
42. Christiansen, E.; Urban, C.; Grundmann, M.; Deu-Hansen, M. E.; Hagesaether, E.; Schmidt, J.; Pardo, L.; Ullrich, S.; Kostenis, E.; Kassack, M.; Ulven, T. Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties J. Med. Chem. 2011, 54, 6691-6703
43. Houze, J. B.; Zhu, L.; Sun, Y.; Akerman, M.; Qiu, W.; Zhang, A. J.; Sharma, R.; Schmitt, M.; Wang, Y.; Liu, J.; Liu, J.; Medina, J. C.; Reagan, J. D.; Luo, J.; Tonn, G.; Zhang, J.; Lu, J. Y-L.; Chen, M.; Lopez, E.; Nguyen, K.; Yang, L.; Tang, L.; Tian, H.; Shuttleworth, S. J.; Lin, D. C. AMG 837: A potent, orally bioavailable GPR40 agonist Bioorg. Med. Chem. Lett. 2012, 22, 1267-1270
44. Hughes, J. D.; Blagg, J.; Price, D. A.; Bailey, S.; Decrescenzo, G. A.; Devraj, R. V.; Ellsworth, E.; Fobian, Y. M.; Gibbs, M. E.; Gilles, R. W.; Greene, N.; Huang, E.; Krieger-Burke, T.; Loesel, J.; Wager, T.; Whiteley, L.; Zhang, Y. Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 2008, 18, 4872-4875
45. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Rev. Drug Discovery 2007, 6, 881-890 (Pubitemid 350042396)
46. Waring, M. J. Lipophilicity in drug discovery Expert Opin. Drug Discovery 2010, 5, 235-248
47. Brown, A. J.; Goldsworthy, S. M.; Barnes, A. A.; Eilert, M. M.; Tcheang, L.; Daniels, D.; Muir, A. I.; Wigglesworth, M. J.; Kinghorn, I.; Fraser, N. J.; Pike, N. B.; Strum, J. C.; Steplewski, K. M.; Murdock, P. R.; Holder, J. C.; Marshall, F. H.; Szekeres, P. G.; Wilson, S.; Ignar, D. M.; Foord, S. M.; Wise, A.; Dowell, S. J. The orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids J. Biol. Chem. 2003, 278, 11312-11319 (Pubitemid 36792688)
48. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120 Nature Med. 2005, 11, 90-94 (Pubitemid 40215843)
49. Hirasawa, A.; Hara, T.; Katsuma, S.; Adachi, T.; Tsujimoto, G. Free fatty acid receptors and drug discovery Biol. Pharm. Bull. 2008, 31, 1847-1851
50. Swaminath, G. Fatty acid binding receptors and their physiological role in type 2 diabetes Arch. Pharm. (Weinheim, Ger.) 2008, 341, 753-761
51. Kebede, M. A.; Alquier, T.; Latour, M. G.; Poitout, V. Lipid receptors and islet function: therapeutic implications? Diabetes, Obes. Metab. 2009, 11, 10-20
52. Berger, J.; Moller, D. E. The mechanisms of action of PPARs Annu. Rev. Med. 2002, 53, 409-435 (Pubitemid 34177889)
53. Boden, G. Effects of free fatty acids (FFA) on glucose metabolism: significance for insulin resistance and type 2 diabetes Exp. Clin. Endocrinol. Diabetes 2003, 111, 121-124 (Pubitemid 36682048)
54. Lam, T. K.; Carpentier, A.; Lewis, G. F.; van de Werve, G.; Fantus, I. G.; Giacca, A. Mechanisms of the free fatty acid-induced increase in hepatic glucose production Am. J. Physiol. Endocrinol. Metab. 2003, 284, E863-E873
55. Yamagami, C.; Ogura, T.; Takao, N. Hydrophobicity parameters determined by reversed-phase liquid chromatography I. Relationship between capacity factors and octanol-water partition coefficients for monosubstituted pyrazines and the related pyridines J. Chromatogr. 1990, 514, 123-136 (Pubitemid 20256620)
56. Ikeda, H.; Shino, A.; Matsuo, T.; Iwatsuka, H.; Suzuoki, Z. A new genetically obese-hyperglycemic rat (Wistar fatty) Diabetes 1981, 30, 1045-1050
57. Li, J.; Edwards, P. C.; Burghammer, M.; Villa, C.; Schertler, G. F. Structure of bovine rhodopsin in a trigonal crystal form J. Mol. Biol. 2004, 343, 1409-1438 (Pubitemid 39387834)
58. Larkin, M. A.; Blackshields, G.; Brown, N. P.; Chenna, R.; McGettigan, P. A.; McWilliam, H.; Valentin, F.; Wallace, I. M.; Wilm, A.; Lopez, R.; Thompson, J. D.; Gibson, T. J.; Higgins, D. G. Clustal W and clustal X version 2.0 Bioinformatics 2007, 23, 2947-2948 (Pubitemid 350162903)
59. MOE, version 2008.10; Chemical Computing Group Inc.: 1010 Sherbrooke St. W, Suite 910 Montreal, Quebec, Canada H3A 2R7, 2008; http://www.chemcomp.com.
60. GOLD, version 4.1; CCDC, Business & Administration, Cambridge Crystallographic Data Centre: 12 Union Road, Cambridge CB2 1EZ, U.K., 2010; http://www.ccdc.cam.ac.uk.